BioCardia, Inc. (NASDAQ:BCDA – Get Rating) CEO Peter Altman bought 13,500 shares of the stock in a transaction on Monday, April 18th. The shares were bought at an average price of $1.39 per share, for a total transaction of $18,765.00. Following the completion of the transaction, the chief executive officer now directly owns 328,143 shares of the company’s stock, valued at approximately $456,118.77. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of BCDA stock traded down $0.05 during trading hours on Monday, hitting $1.44. The company’s stock had a trading volume of 619,677 shares, compared to its average volume of 1,709,109. The stock has a fifty day moving average of $2.08. The firm has a market capitalization of $24.29 million, a PE ratio of -1.92 and a beta of 1.32. BioCardia, Inc. has a twelve month low of $1.25 and a twelve month high of $5.10.
BioCardia (NASDAQ:BCDA – Get Rating) last released its quarterly earnings results on Tuesday, March 29th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.01. BioCardia had a negative net margin of 1,243.65% and a negative return on equity of 87.02%. During the same period last year, the firm earned ($0.16) EPS. Analysts anticipate that BioCardia, Inc. will post -1.05 EPS for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in BCDA. Commonwealth Equity Services LLC acquired a new stake in BioCardia during the third quarter worth approximately $51,000. Millennium Management LLC acquired a new stake in BioCardia during the third quarter worth approximately $31,000. Finally, Virtu Financial LLC acquired a new stake in BioCardia during the fourth quarter worth approximately $109,000. Hedge funds and other institutional investors own 14.86% of the company’s stock.
About BioCardia (Get Rating)
BioCardia, Inc, a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease.
- Get a free copy of the StockNews.com research report on BioCardia (BCDA)
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
- Tapestry Stock is a Value Play Down Here
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.